Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
In this study doxorubicin, epirubicin, and mitoxantrone were compared for their cardiotoxic potential in a chronic mouse model in an effort to identify and compare their mechanism(s) of toxicity. In addition, the cardioprotective ability of ICRF-187 [(+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] with each anticancer drug was evaluated in this model. The antioxidant capacity (superoxide dismutase, reduced glutathione, catalase, and glutathione peroxidase) was assessed following drug treatment. Five-week-old BALB/c mice received weekly i.p. injections of each drug or the drug and ICRF-187 over a 3-month period. ICRF-187 was administered 30 min prior to the anticancer drug. The hearts were examined by electron and light microscopy to assess subcellular changes, and the cardiac and hepatic antioxidant levels were measured concurrently. Chronic treatment with these drugs or each combined with ICRF-187 did not change the antioxidant levels relative to the control values. However, all three drugs caused cardiac damage during chronic exposure. Both epirubicin and mitoxantrone caused less severe damage than doxorubicin, and epirubicin was the least cardiotoxic of the three. ICRF-187 was cardioprotective for epirubicin and doxorubicin but not for mitoxantrone. These results suggest epirubicin acts by a mechanism similar to that of doxorubicin that is probably mediated by oxygen-free radicals, while mitoxantrone acts by a different mechanism to cause cardiotoxicity.
Alderton
P M
PM
Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Gross
J
J
Green
M D
MD
D000818:Animals; D004317:Doxorubicin / Q000009:adverse effects*; D015251:Epirubicin / Q000009:adverse effects*; D005260:Female; D006321:Heart / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D008942:Mitoxantrone / Q000009:adverse effects*; D009206:Myocardium / Q000473:pathology* / Q000648:ultrastructure; D011292:Premedication; D011897:Random Allocation; D011929:Razoxane / Q000494:pharmacology*
D015251:Epirubicin; D011929:Razoxane; D004317:Doxorubicin; D008942:Mitoxantrone